A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Administration and Multiple-Administration Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of IMBZ18g in Healthy Chinese Subjects

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 4c6090d47376d60e8a3445021327743ae2905b82
First added on: Apr 23, 2026